Working… Menu
Trial record 69 of 231 for:    CALCITONIN SALMON

Ibudilast in the Treatment of Patients With Chronic Migraine. (IBU-003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01389193
Recruitment Status : Completed
First Posted : July 8, 2011
Last Update Posted : December 29, 2015
The Ministry of Science, Technology and Innovation, Denmark
Migraine Research Foundation
Information provided by (Responsible Party):
Parisa Gazerani, Aalborg University

Brief Summary:

This will be a double-blind, randomised, placebo-controlled, two period cross over study of ibudilast in the treatment of chronic migraine.

For participants resident in Adelaide, South Australia (i.e. "local participants"):

The study will involve a screening visit followed by eight visits to the Pain and Anaesthesia Research Clinic (PARC), within the Royal Adelaide Hospital (RAH), for baseline testing, initiation of the study medications and ongoing data collection (one baseline and three study visits during each treatment period).

At the baseline visit, blood samples to assess biomarkers (glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100β) will be taken. Patients will then be randomised (in a 1:1 ratio) to commence either ibudilast or placebo treatment, which will continue for 8 weeks. Subsequently participants will undergo a 4-week washout period. At the end of the washout period a second 8-week treatment block with the alternative treatment will commence.

Patients will complete a headache diary daily for at least 4 weeks prior to the baseline visit, throughout the treatment and washout periods and for 4 weeks after treatment ceases. The diary will record headache frequency, duration, intensity, pain characteristics and medication intake for comparison with baseline data.

From screening until the final study visit (over a minimum of 6 months) a total of approximately 200 mL in blood samples will be taken from each local participant.

For participants located in country or interstate locations:

The same study will be undertaken, but instead of attending the Pain and Anaesthesia Research Clinic (PARC), within the Royal Adelaide Hospital (RAH) for screening and study visits, these will be managed remotely through:

basic input from the participant's GP during the screening period correspondence with the PI and study staff via registered post, phone or Skype scheduled visits to the nearest pathology collection centre for blood biochemistry and haematology analysis

Interstate or country participants will also be exempt from collection of blood samples for biomarker analysis, hence a total of approximately 120 mL of blood samples will be taken from each interstate or country participant.

Condition or disease Intervention/treatment Phase
Migraine Headache Drug: Ibudilast Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Targeting Glial Inhibition to Attenuate Chronic Migraine: AN INTERNATIONAL DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF IBUDILAST
Study Start Date : June 2013
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache Migraine

Arm Intervention/treatment
Experimental: Ibudilast Drug: Ibudilast
Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
Other Name: Ibudilast (Ketas® 10 mg capsules) manufactured by Kyorin Pharmaceuticals.

Placebo Comparator: Placebo Drug: Placebo
Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
Other Name: Pharmaceutical Packaging Professionals, West Thebarton Rd, Thebarton, South Australia

Primary Outcome Measures :
  1. Primary efficacy end point [ Time Frame: 8 weeks ]

    As suggested by the IHS guidelines for clinical trials in chronic migraine, the primary efficacy endpoint will be number of headache days per month with moderate or severe intensity. Study outcomes will be assessed at baseline and at weeks 2, 4 and 8 of each treatment period.

    To monitor treatment with ibudilast, blood biochemistry (including assessment of renal and hepatic including GGT function) and haematology will be assessed at baseline, and at weeks 2, 4 and 8 of each treatment period. Patients will also be screened for adverse effects via questionnaire at each visit during treatment.

Secondary Outcome Measures :
  1. Secondary efficacy end points [ Time Frame: 8 weeks ]

    The secondary end points assessed will include:

    • Migraine frequency (number of days with migraine of any severity/month)
    • Migraine episode frequency (number of migraine episodes/month)
    • Medication frequency (number of days acute headache medication taken/month)
    • Headache related impact on quality of life as assessed using the HIT-6
    • Cutaneous allodynia as assessed using the ASC-12
    • Biomarker levels

  2. Serum biomarker levels [ Time Frame: 8 weeks ]
    To determine if serum levels of the following potential biomarkers are able to differentiate response to treatment with ibudilast: glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100 calcium binding protein β.

Other Outcome Measures:
  1. safety and tolerability of ibudilast [ Time Frame: 8 weeks ]
    Ibudilast 40 mg or placebo twice daily for 8 weeks is effective and safe in a chronic migraine population.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Men and women aged between 18 to 65 years Migraine with or without aura, as diagnosed according to the second edition International Classification of Headache Disorders (ICHD-II) Onset of migraine before 50 years of age Headache on 15 or more days per month Migraine-like headache on 8 or more days per month, as per the IHS guidelines

Exclusion Criteria:

  • Change in type or dose of migraine prophylactic medication in last 3 months
  • Medication overuse headache as diagnosed according to the ICHD-IIR
  • Post-traumatic headache as diagnosed according to the ICHD-II
  • Other dominant chronic pain condition
  • Known active inflammatory diseases such as rheumatoid arthritis
  • History of recent cerebrovascular disorder
  • Unable to provide written informed consent
  • Unable to read and write in English
  • Severe psychological/psychiatric disorders
  • Recent history of significant trauma, as determined by the Principal Investigator including major surgery within the previous 2 months or major surgery planned during the treatment period
  • Recent history of drug or alcohol abuse
  • Any clinically significant findings on screening blood sample results
  • Current malignancy
  • Known hypersensitivity to ibudilast or excipients in Ketas® formulation
  • Renal or hepatic impairment, defined as baseline GFR (as calculated by the Cockcroft-Gault equation) of <60 mL/min, LFTs (excluding bilirubin) > 3 times the upper limit of normal or bilirubin > 2 times the upper limit of normal
  • For females of childbearing potential:

    • Pregnancy
    • Lack of adequate contraception (abstinence, double barrier method, intrauterine device, surgical sterilization (self or partner), hormonal contraceptive methods (oral, injected, or implanted)
    • Breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01389193

Layout table for location information
School of Medical sciences, University of Adelaide
Adelaide, Australia
Sponsors and Collaborators
Parisa Gazerani
The Ministry of Science, Technology and Innovation, Denmark
Migraine Research Foundation
Layout table for investigator information
Principal Investigator: Paul Rolan, MBBS FRACP FFPM MD School of Medical sciences, University of Adelaide, Adelaide, Australia
Principal Investigator: Parisa Gazerani, PharmD, PhD Aalborg University

Layout table for additonal information
Responsible Party: Parisa Gazerani, Associtae professor, Aalborg University Identifier: NCT01389193     History of Changes
Other Study ID Numbers: IBU-003
MRF and DRC ( Other Grant/Funding Number: Migraine Research Foundation, Danish Research Council )
First Posted: July 8, 2011    Key Record Dates
Last Update Posted: December 29, 2015
Last Verified: December 2015
Keywords provided by Parisa Gazerani, Aalborg University:
glial cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Vasodilator Agents